Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?
Oktávia Tarjányi1, Katalin Olasz2, Fanni Rátky1
1Department of Medical Biology, Medical School, University of Pecs, H-7624 Pecs, Hungary.
International Journal of Molecular Sciences
|April 17, 2025
Summary
Proteasome inhibitors show promise for treating rheumatoid arthritis (RA), a chronic autoimmune disease. These agents may offer new therapeutic options for RA patients, potentially improving outcomes when used alone or with existing treatments.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune condition causing joint destruction.
- Current biological therapies offer limited complete remission for RA patients.
- Novel therapeutic strategies for RA are actively being investigated.
Purpose of the Study:
- To review the potential therapeutic effects of proteasome inhibitors (PIs) in rheumatoid arthritis.
- To summarize existing evidence from animal and human studies on PIs for RA.
- To explore PIs as a novel treatment avenue for RA.
Main Methods:
- Literature review of studies on proteasome inhibitors and rheumatoid arthritis.
- Analysis of data from animal models of RA.
- Examination of human clinical data regarding PI efficacy and safety in RA.
Main Results:
- Proteasome inhibitors target the NF-κB pathway, crucial in RA inflammation.
- PIs have demonstrated inhibition of cell activation and induction of apoptosis in relevant models.
- Evidence suggests PIs possess anti-inflammatory and joint-protective properties in RA contexts.
Conclusions:
- Proteasome inhibitors hold significant potential for RA therapy.
- PIs may be effective as monotherapy or in combination with current RA medications.
- Further research into PIs could lead to improved management of rheumatoid arthritis.
Related Concept Videos
02:18The Proteasome
8.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.3K
01:24T Cell Types and Functions
619
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
619
01:20The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97